CDC finds lower RSV hospitalization rates for infants receiving prevention products
The Centers for Disease Control and Prevention May 8 released an analysis that found declines in hospitalizations for infants infected with respiratory syncytial virus during the 2024-2025 RSV season — the first with widespread availability of the maternal RSV vaccine and nirsevimab, a long-acting monoclonal antibody. Rates were 45% to 52% lower for infants less than 3 months old and 28% to 43% lower for those less than 8 months old. As of February, an estimated 66% of infants received either the maternal RSV vaccine or nirsevimab during the 2024-2025 season.
Related News Articles
Headline
President Trump signed an executive order May 29 that directs the Centers for Disease Control and Prevention and the Advisory Committee on Immunization…
Headline
The AHA and other national health care groups sent a letter to members of the House and Senate appropriations committees, urging them to provide $1.…
Headline
The U.S. birth rate declined by 1% in 2025, according to preliminary data released by the Centers for Disease Control and Prevention. The cesarean delivery…
Headline
The AHA and Epic are launching the Safer Births PPH Collaborative, a seven-month initiative designed to support hospitals in reducing postpartum hemorrhage…
Headline
The AHA Feb. 17 submitted a comment letter responding to the Centers for Medicare & Medicaid Services’ proposed rule that would prohibit hospitals…
Headline
A new blog shares key takeaways from the AHA’s Better Health for Mothers and Babies webinar series, where hospitals share how they are putting the initiative’s…